Company intelligence / Profile preview

JOYSBIO

Ownership: Private
Development stage: Commercial

Overview

JOYSBIO has developed and commercialized a broad portfolio of rapid in vitro diagnostic tests using lateral flow technology. Their products are widely used for the detection of infectious diseases, tumor and cardiac markers, pregnancy, drugs of abuse, and more. During the COVID-19 pandemic they supplied over two hundred million SARS-CoV-2 rapid test kits globally. They have also launched new monkeypox rapid tests.

No clinical trial data as these are diagnostic devices; performance data available per product.

Products are ISO13485 certified.

Therapeutic areas: OncologyInfectious DiseasesPsychiatryCardiovascularWomen's Health
Modalities: DeviceDiagnostic test kit (Lateral flow assay)Reagent kit
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on JOYSBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JOYSBIO.

Explore the full profile